Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127428781 | 12742878 | 1 | I | 20160907 | 0 | 20160914 | 20160914 | DIR | FDA-CTU | 41.27 | YR | M | N | 84.10000 | KG | 20160913 | N | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127428781 | 12742878 | 1 | PS | 5-FLUOROURACIL (5-FU) | FLUOROURACIL | 1 | 0 | 5090 | MG | ||||||||||
| 127428781 | 12742878 | 2 | SS | LEUCOVORIN CALCIUM. | LEUCOVORIN CALCIUM | 1 | 0 | 848 | MG | ||||||||||
| 127428781 | 12742878 | 3 | SS | ELOXATIN | OXALIPLATIN | 1 | 0 | ||||||||||||
| 127428781 | 12742878 | 5 | C | IRINOTECAN | IRINOTECAN | 1 | 0 |
Indications of drugs used
| no results found |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127428781 | 12742878 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127428781 | 12742878 | Asthenia | |
| 127428781 | 12742878 | Dizziness | |
| 127428781 | 12742878 | Hyperhidrosis | |
| 127428781 | 12742878 | Hyponatraemia | |
| 127428781 | 12742878 | Lipase increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127428781 | 12742878 | 1 | 20160907 | 0 | ||
| 127428781 | 12742878 | 2 | 20160907 | 0 | ||
| 127428781 | 12742878 | 3 | 20160727 | 0 |